High occurrence of CYP3A5 variants among breast cancer and organ transplant patients

Ismail, S and Mohammad, NI and Hamzah, S and Mohamad , R and Harun, R and Suhaimi, S and Jaszle, S and Sood, S and Henry, F and Shabery, A and Rajoo, T and Bahri, R and Muniandy, S and Ismail, G and Wong, H. S. and Abdullah Ngow, Harris and U Kyaw, T. H. and Jalaludin, K and Din, J and Hatta, F. H. and Teh, L. K. and Salleh, M. Z. (2010) High occurrence of CYP3A5 variants among breast cancer and organ transplant patients. In: National Committee For Clinical Research(NCCR) 2010- 13th NIH Scientific Meeting, 2- 4 June 2010, Royale Chulan, Kuala Lumpur.

PDF (High occurrence of CYP3A5 variants among breast cancer and organ transplant patients) - Presentation Restricted to Repository staff only Download (174kB) | Request a copy

Abstract

Abstract CYP3A5 is one of the important drug metabolising enzyme and its polymorphism shows marked differences in protein expression and catalytic activities between different geographical ethnic groups. Both tamoxifen and tacrolimus are substrates of CYP3A5 and thus the polymorphism may cause pharmacokinetics variation which explains the wide variaton in the dose requirement and patients’s responses. CYP3A5*3 (A22893G) allele resulted in a truncated protein with loss of CYP3A5 expression whilst the CYP3A5*6 (G 30597A) allele caused deletion of exon 6 from the splice variant and was associated with lower CYP3A5 catalytic activity. Both of these polymorphisms lead to the inability of an individual to express full functional CYP3A5. Aim This study aims to investigate the frequency of CYP3A5 haplotypes among healthy volunteers, breast cancer and kidney transplant patients in selected hospitals. Methods This study was approved by the Medical Research Ethic Committee and local institution. Subjects were screened for inclusion and exclusion criteria and recruited after informed consent. Five ml of blood was obtained from subjected and DNA was extracted and subjected to genotyping of CYP3A5 variants. Multiplex PCR were designed with novel primers specific to 3’ end that amplify the variants of A6986G and G14690A. The optimized method was validated by direct sequencing. Result Twelve breast cancer patients (tamoxifen therapy), 6 organ transplant patients (tacrolimus therapy) and 264 healthy blood donors (98 Malay and Chinese; 74 Indian) were successfully recruited. CYP3A5 is highly polymorphic in the Malaysian populations with the *3 allele having a frequency of more than 60% among the healthy volunteers. The frequency of *3 allele was lower (54.17%) in breast cancer patients. All the 6 patients treated with tacrolimus carry at least one mutated variant (1 patient was heterozygous and 5 were homozygous CYP3A5*3). CYP3A5 *6 allele was absent all patients. Conclusion High percentage of patients and volunteers carry at least one CYP3A5*3 allele and this may be an important genetic contributor to interindividual as well as interethnic differences in the clearance of CYP3A5 substrates. However, we are conducting an on-going study with a larger sample size of the patients to understand the impact of pharmacodiagnostics of drug metabolizing enzyme and drug receptors in local clinical settings.

Item Type:	Conference or Workshop Item (Poster)
Additional Information:	4393/5235
Uncontrolled Keywords:	CYP3A5, breast cancer, organ transplant, kidney transplant
Subjects:	R Medicine > RB Pathology R Medicine > RC Internal medicine
Kulliyyahs/Centres/Divisions/Institutes (Can select more than one option. Press CONTROL button):	Kulliyyah of Medicine > Department of Internal Medicine
Depositing User:	Associate Professor Dr Harris Ngow Abdullah
Date Deposited:	17 Jan 2012 12:33
Last Modified:	17 Jan 2012 12:33
URI:	http://irep.iium.edu.my/id/eprint/5235

Actions (login required)

View Item